KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Gross Margin (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Gross Margin for 17 consecutive years, with 67.23% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 622.0% to 67.23% in Q4 2025 year-over-year; TTM through Dec 2025 was 71.08%, a 0.0% change, with the full-year FY2025 number at 71.08%, changed 0.0% from a year prior.
  • Gross Margin was 67.23% for Q4 2025 at Bristol Myers Squibb, down from 71.9% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 80.34% in Q4 2021 to a low of 61.01% in Q4 2024.
  • A 5-year average of 75.02% and a median of 75.69% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: surged 831bps in 2021, then tumbled -1507bps in 2024.
  • Bristol Myers Squibb's Gross Margin stood at 80.34% in 2021, then dropped by -4bps to 77.27% in 2022, then dropped by -2bps to 76.08% in 2023, then decreased by -20bps to 61.01% in 2024, then rose by 10bps to 67.23% in 2025.
  • Per Business Quant, the three most recent readings for BMY's Gross Margin are 67.23% (Q4 2025), 71.9% (Q3 2025), and 72.52% (Q2 2025).